Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Vulture contributor Fran Hoepfner talks the Wicked film's marketing campaign, why 'culture jacking' works so well and how it all paid off for the hit musical.
Brigit Zimmerman, Chief Commercial Officer at Priceline breaks down what travelers can expect this holiday season, predictions for 2025 and best ways to save.
Simon Shuster, Senior Correspondent at TIME, discusses his recent article, how the friendship between Musk and Trump may affect US spending, “DOGE” and more.
Christa Pitts, Co-Founder & Co-CEO of The Lumistella Company shares the origins of Elf on the Shelf Plus Extraordinary Noorah's Macy's Day Parade debut!
Hayley Berg, Lead Economist at Hopper breaks down her best tips for navigating holiday travel and how to score the hottest deals on Dec. 3 - Travel Deal Tuesday
MarketWatch's Hannah Erin Lang joins Cheddar to discuss how economists are viewing Trump's immigration policy and how it will affect the job market in America.
